A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
A study patients with Diffuse Large B-Cell Lymphoma using study drug Ublituximab
Sponsor: TG Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ9773
U.S. Govt. ID: NCT02793583
Contact: Owen O'Connor: 212-326-5720 / oo2130@cumc.columbia.edu
Additional Study Information: This study is being done to see how effective two investigational drugs, ublituximab and TGR-1202 are when given together. This study will also see how effective TGR-1202 is when given alone.
This study is closed
Investigator
Owen O'Connor, MD, PhD
Do You Qualify?
Have you been diagnosed with Diffuse Large B-Cell Lymphoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Owen O'Connor
oo2130@cumc.columbia.edu
212-326-5720
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE